Generated by All in One SEO v4.9.7.2, this is an llms.txt file, used by LLMs to index the site.

# Asabys Partners

Investing across the board in human healthcare

## Sitemaps

- [XML Sitemap](https://asabys.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Nuage Therapeutics raises €12M in Seed Financing led by Sofinnova Partners and Asabys](https://asabys.com/nuage-therapeutics-raises-e12m/) - Our recent activity Nuage Therapeutics raises €12M in Seed Financing led by Sofinnova Partners and Asabys READ THIS NEWS IN SPANISH The technology developed by Nuage Therapeutics allows targeting intrinsically disordered proteins with drug-like small molecules The seed financing will advance the lead program, for castration resistant prostate cancer, and validate its drug discovery platform
- [Oriva Therapeutics appoints Dr Agnès Arbat as CEO to advance clinical-stage women’s health pipeline](https://asabys.com/dr-agnes-arbat-as-ceo/) - Our recent activity Oriva Therapeutics appoints Dr Agnès Arbat as CEO to advance clinical-stage women’s health pipeline READ THIS NEWS IN SPANISH Oriva is developing innovative medicines for chronic gynaecological diseases and is backed by pre-seed financing from Asabys Partners’ Sabadell Asabys II fund Dr Arbat brings over 25 years’ pharma industry experience, including roles
- [Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development](https://asabys.com/ona-therapeutics-raises-86m/) - Our recent activity Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development READ THIS NEWS IN SPANISH Oversubscribed Series B financing co-led by new investors Columbus Venture Partners and Mérieux Equity Partners, with participation from additional investors COFIDES and Korys, alongside all existing investors Proceeds to support clinical development of
- [Asabys Announces a New Life Sciences Fund Following Its Selection in the CDTI and EIF Innvierte Deep Start Initiative](https://asabys.com/new-life-sciences-fund/) - Our recent activity Asabys Announces a New Life Sciences Fund Following Its Selection in the CDTI and EIF Innvierte Deep Start Initiative READ THIS NEWS IN SPANISH Asabys launches a fund of up to €120M to transform scientific discoveries into innovative healthcare companies, reinforcing its commitment to technology transfer and the creation of deep tech
- [The Ministry of Science, Innovation and Universities, through CDTI, and the EIF invest €74.7 million in the Asabys Innvierte Tech Transfer fund to boost innovation and company creation in biotechnology and medical technologies](https://asabys.com/74-7-million-in-asabys/) - Our recent activity The Ministry of Science, Innovation and Universities, through CDTI, and the EIF invest €74.7 million in the Asabys Innvierte Tech Transfer fund to boost innovation and company creation in biotechnology and medical technologies READ THIS NEWS IN SPANISH Second transaction under the Innvierte Deep Start framework, an instrument created by CDTI Innvierte
- [Medasense Appoints MedTech Leader Peter Wehrly as Executive Chairman of the Board](https://asabys.com/medasense-appoints-peter-wehrly/) - Our recent activity Medasense Appoints MedTech Leader Peter Wehrly as Executive Chairman of the Board Medasense today announced the appointment of Peter Wehrly as Executive Chairman of the Board. Over the past 15 years, Mr. Wehrly has led and advised innovative medical technology companies through pivotal inflection points, including regulatory approval, US market entry, and
- [Orikine Bio appoints Larry Edwards as Chairman of the Board](https://asabys.com/larry-edwards/) - Our recent activity Orikine Bio appoints Larry Edwards as Chairman of the Board Orikine Bio, a biotechnology company based at the Barcelona Science Park (PCB-UB), today announced the appointment of Larry Edwards as Chairman of its Board of Directors, effective 1 January 2026. His incorporation strengthens the company’s governance and supports its strategic vision as
- [Asabys-backed Oriva Therapeutics launches to advance novel treatments for women’s health](https://asabys.com/asabys-backed-oriva-therapeutics-launches-to-advance-novel-treatments-for-womens-health/) - Our recent activity Asabys-backed Oriva Therapeutics launches to advance novel treatments for women’s health READ THIS NEWS IN SPANISH Oriva Therapeutics is launched with the support of Asabys, focused on developing innovative therapies in women’s health The company incorporates two advanced assets from Oncostellae and Medibiofarma, addressing two high-unmet-need chronic conditions in women: endometriosis and
- [Agomab Announces Positive Phase 1 Interim Results with AGMB-447 in Healthy Participants and Initiation of Idiopathic Pulmonary Fibrosis Cohort](https://asabys.com/agomab-announces-positive-phase-1/) - Our recent activity Agomab Announces Positive Phase 1 Interim Results with AGMB-447 in Healthy Participants and Initiation of Idiopathic Pulmonary Fibrosis Cohort Interim data from Phase 1 with single and multiple ascending doses show no safety signals and a generally favorable tolerability profile of AGMB-447 in healthy participants Pharmacokinetic profile in healthy participants shows low
- [SafeHeal® Announces Successful Launch of SAFE-3CV IDE Study for Colovac® Anastomosis Protection Technology](https://asabys.com/safeheal-successful-launch/) - Our recent activity SafeHeal® Announces Successful Launch of SAFE-3CV IDE Study for Colovac® Anastomosis Protection Technology Breakthrough device promises significantly improved patient recovery after colorectal surgery SafeHeal®, a leading innovator in the field of colorectal cancer surgery, today announced the first patient enrollment in its pivotal IDE study of Colovac®, a groundbreaking endoluminal bypass sheath.
- [INBRAIN Neuroelectronics Appoints Scott  Huennekens as Chairman of the Board](https://asabys.com/scott-huennekens/) - Our recent activity INBRAIN Neuroelectronics Appoints Scott Huennekens as Chairman of the Board INBRAIN Neuroelectronics, a brain-computer interface therapeutics (BCI-Tx} company developing graphene-based neural technologies, today announced the appointment of Scott Huennekens as Chairman of its Board of Directors. Mr. Huennekens joins the company as INBRAIN accelerates development of its next-generation graphene-based BCI therapeutics into
- [Agomab Announces Positive Topline Phase 2a Data for Ontunisertib in Fibrostenosing Crohn’s Disease](https://asabys.com/agomab-announces-positive-topline-phase-2a/) - Our recent activity Agomab Announces Positive Topline Phase 2a Data for Ontunisertib in Fibrostenosing Crohn’s Disease STENOVA trial achieves primary endpoint in 103 study participants after 12 weeks of treatment Pharmacokinetic results confirm gut-restricted profile of ontunisertib in FSCD patients Positive efficacy signals observed for several exploratory clinical endpoints Ongoing open-label extension study supports longer-term
- [Qida raises €37 million to continue improving the quality of life of the senior segment at home](https://asabys.com/qida-raises-e37-million/) - Our recent activity Qida raises €37 million to continue improving the quality of life of the senior segment at home READ THIS NEWS IN SPANISH The round is led by Quadrille Capital and co-led by Asabys Partners and COFIDES (Social Impact Fund). ICF and Endeavor Catalyst also join the round Existing investors also participate in
- [Ona Therapeutics, a portfolio company of Asabys Partners and Alta Life Sciences, appoints Dr. Antoine Yver as Chair of the Board to accelerate its ADC programs towards clinical development](https://asabys.com/dr-antoine-yver-as-chair/) - Our recent activity Ona Therapeutics, a portfolio company of Asabys Partners and Alta Life Sciences, appoints Dr. Antoine Yver as Chair of the Board to accelerate its ADC programs towards clinical development • Brings over 35 years of oncology drug development experience, including senior executive leadership roles at AstraZeneca and Daiichi Sankyo • Led the
- [AltamarCAM and Asabys agree to integrate Aliath, their life sciences unit, into Asabys](https://asabys.com/altamarcam-and-asabys-integrate-aliath/) - Our recent activity AltamarCAM and Asabys agree to integrate Aliath, their life sciences unit, into Asabys READ THIS NEWS IN SPANISH The resulting team will manage over €400M in investments in biotechnology and medical technologies. Management of the Alta Life Sciences Spain I FCR fund will be reinforced with the incorporation of Clara Campàs and
- [Asabys Partners Leads €10 Million Extension of SafeHeal’s Oversubscribed Series C Financing to Accelerate Commercialization of Colovac®](https://asabys.com/leads-10-million-colovac/) - Our recent activity Asabys Partners Leads €10 Million Extension of SafeHeal’s Oversubscribed Series C Financing to Accelerate Commercialization of Colovac® READ THIS NEWS IN SPANISH Asabys joins SafeHeal’s global investor syndicate, which includes Sofinnova, Solar Eclipse and a Leading Multinational Life Sciences Corporation, bringing additional resources and strategic expertise to advance pivotal U.S. trial and
- [SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines](https://asabys.com/splicebio-secures-135-million/) - Our recent activity SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines READ THIS NEWS IN SPANISH Financing co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as all existing investors Proceeds will support
- [Deepull secures oversubscribed €50 million Series C financing to advance UllCORE diagnostic system for direct-from-blood rapid pathogen detection](https://asabys.com/deepull-secures-oversubscribed-e50-million-series-c-financing-to-advance-ullcore-diagnostic-system-for-direct-from-blood-rapid-pathogen-detection/) - Our recent activity Deepull secures oversubscribed €50 million Series C financing to advance UllCORE diagnostic system for direct-from-blood rapid pathogen detection READ THIS NEWS IN SPANISH Round co-led by Columbus Venture Partners, Panakès Partners and Mérieux Equity Partners Deepull, a medical diagnostics company developing culture-free diagnostic solutions for rapid pathogen identification, announced today the successful
- [Three Asabys-Backed Biotechs Featured in Nature, Showcasing Spain's Scientific Innovation](https://asabys.com/three-asabys-backed-biotechs-featured-in-nature-showcasing-spains-scientific-innovation/) - Our recent activity Three Asabys-Backed Biotechs Featured in Nature, Showcasing Spain's Scientific Innovation READ THIS NEWS IN SPANISH READ THIS NEWS IN CATALAN Nature, the world’s leading scientific journal, has spotlighted three Barcelona-based biotech startups, Ona Therapeutics, Nuage Therapeutics, and SpliceBio, in a recent article highlighting Spain’s burgeoning life sciences sector. All three companies were
- [Nuage Therapeutics appoints Dr. Stuart Hughes as CEO  and Vanessa Malier as Chair](https://asabys.com/nuage-therapeutics-appoints-dr-stuart-hughes-as-ceo-and-vanessa-malier-as-chair/) - Our recent activity Nuage Therapeutics appoints Dr. Stuart Hughes as CEO and Vanessa Malier as Chair Experienced R&D leader and biotech entrepreneur, Stuart Hughes, appointed as Chief Executive Officer Life sciences executive and healthcare investor, Vanessa Malier appointed as Chair of the Board of Directors Nuage Therapeutics applying its proprietary technology to advance a pipeline
- [Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round](https://asabys.com/augustine-therapeutics-raises-oversubscribed-eur-78-million-usd-85-million-series-a-financing-round/) - Our recent activity Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round READ THIS NEWS IN SPANISH Novo Holdings and Jeito Capital co-led the deal, supported by Asabys Partners and existing investors Proceeds to support the clinical development of lead candidate AGT-100216 for the treatment of Charcot-Marie-Tooth (CMT) disease,
- [Quibim Announces $50 Million in Series A Financing, led by Asabys and Buenavista, to Revolutionize Precision Medicine with AI-Powered Imaging Biomarkers](https://asabys.com/quibim-announces-50-million-in-series-a-financing-led-by-asabys-and-buenavista-to-revolutionize-precision-medicine-with-ai-powered-imaging-biomarkers/) - Our recent activity Quibim Announces $50 Million in Series A Financing, led by Asabys and Buenavista, to Revolutionize Precision Medicine with AI-Powered Imaging Biomarkers READ THIS NEWS IN SPANISH Funding drives the expansion of Quibim’s product pipeline and foundational AI models and accelerates global commercial growth. Asabys and Buenavista lead the round, joined by UI
- [Anaconda Biomed Appoints Trent Reutiman New CEO](https://asabys.com/anaconda-biomed-appoints-trent-reutiman-new-ceo/) - Our recent activity Anaconda Biomed Appoints Trent Reutiman New CEO Seasoned Medtech Executive to Expand Company Presence Into U.S. Anaconda Biomed S.L., a medical technology company developing next-generation thrombectomy systems for the treatment of ischemic stroke, has announced that it has named long-time medtech executive Trent Reutiman as its new CEO. Based in California’s San Francisco Bay
- [Deepull receives FDA Breakthrough Device Designation for its UllCORE Bloodstream Infection Test](https://asabys.com/deepull-receives-fda-breakthrough-device-designation-for-its-ullcore-bloodstream-infection-test/) - Our recent activity Deepull receives FDA Breakthrough Device Designation for its UllCORE Bloodstream Infection Test READ THIS NEWS IN SPANISH Deepull, empresa de diagnóstico médico que desarrolla soluciones de diagnóstico sin cultivos para la identificación rápida de patógenos, ha anunciado hoy que ha recibido la designación de dispositivo innovador Breakthrough Device Designation de la agencia
- [INBRAIN Neuroelectronics Raises $50M Series B to Advance Graphene-Based Brain-Computer Interface Technology](https://asabys.com/inbrain-neuroelectronics-raises-50m-series-b-to-advance-graphene-based-brain-computer-interface-technology/) - Our recent activity INBRAIN Neuroelectronics Raises $50M Series B to Advance Graphene-Based Brain-Computer Interface Technology READ THIS NEWS IN SPANISH VC funding led by imec.xpand, with significant participation from the EIC Fund (venture arm of the European Innovation Council) and continued support from existing investors Asabys Partners and Aliath Bioventures. Funding will be used to
- [Agomab Announces $89 Million Series D Financing to Support Broad Fibrosis-focused Pipeline](https://asabys.com/agomab-announces-89-million-series-d-financing-to-support-broad-fibrosis-focused-pipeline/) - Our recent activity Agomab Announces $89 Million Series D Financing to Support Broad Fibrosis-focused Pipeline READ THIS NEWS IN SPANISH Round includes participation from new investors Sanofi and Invus, as well as existing investors Proceeds will fund clinical development of lead candidate AGMB-129 in fibrostenosing Crohn’s disease, AGMB-447 in idiopathic pulmonary fibrosis and AGMB-101 in
- [Gradient Denervation Technologies Appoints Stanton Rowe to Board of Directors and Receives FDA Approval to Expand Early Feasibility Study](https://asabys.com/gradient-denervation-technologies-appoints-stanton-rowe-to-board-of-directors-and-receives-fda-approval-to-expand-early-feasibility-study/) - Our recent activity Gradient Denervation Technologies Appoints Stanton Rowe to Board of Directors and Receives FDA Approval to Expand Early Feasibility Study Serial entrepreneur and medical device industry executive adds key experience to board of directors Gradient Denervation Technologies, a Paris-based medical device company developing a minimally-invasive, ultrasound-based catheter system designed to treat pulmonary hypertension
- [Asabys Announces the Closing of €180M Oversubscribed  Sabadell Asabys II Fund](https://asabys.com/asabys-announces-the-closing-of-e180m-oversubscribed-sabadell-asabys-ii-fund/) - Our recent activity Asabys Announces the Closing of €180M Oversubscribed Sabadell Asabys II Fund READ THIS NEWS IN SPANISH New fund is investing across the board in life sciences to improve patient outcomes Similar to Sabadell Asabys Fund I, the Fund II portfolio will include companies within the fields of biopharma, medtech and digital health
- [Augustine Therapeutics Raises Eur 17 Million In A Series A First Closing To Advance Lead Candidate Into Clinical Development In Neurological Diseases](https://asabys.com/augustine-therapeutics-raises-eur-17-million-in-a-series-a-first-closing-to-advance-lead-candidate-into-clinical-development-in-neurological-diseases/) - Our recent activity Augustine Therapeutics Raises Eur 17 Million In A Series A First Closing To Advance Lead Candidate Into Clinical Development In Neurological Diseases READ THIS NEWS IN SPANISH Proceeds will advance lead candidate AGT100216, a peripherally restricted and selective HDAC6 inhibitor, into a first-in-human clinical Phase 1/2 study Gerhard Koenig appointed as executive
- [Deepull appoints Didier Deltort to its Board of Directors](https://asabys.com/deepull-appoints-didier-deltort-to-its-board-of-directors/) - Our recent activity Deepull appoints Didier Deltort to its Board of Directors Deepull, a medical diagnostics company developing culture-free diagnostic solutions for rapid pathogen identification for sepsis and other acute infections, today announces the appointment of Didier Deltort to its Board of Directors. Didier Deltort is a Senior Advisor at Mérieux Equity Partners. Didier has
- [Norrsken Foundation y Asabys estrenan Doctropreneurs en el marco de su acuerdo de colaboración en el emprendimiento de impacto](https://asabys.com/norrsken-foundation-y-asabys-estrenan-doctropreneurs-en-el-marco-de-su-acuerdo-de-colaboracion-en-el-emprendimiento-de-impacto/) - Our recent activity Norrsken Foundation y Asabys estrenan Doctropreneurs en el marco de su acuerdo de colaboración en el emprendimiento de impacto El pasado jueves 22 de marzo, tuvo lugar la sesión inaugural de Doctopreneurs MeetUp en Norrsken Club Barcelona en Passeig del Mare Nostrum. Doctopreneurs nace como iniciativa de The Asabys Institute, el área
- [Gradient Denervation Technologies Enrolls First Patient in Early Feasibility Study of Pulmonary Artery Denervation System](https://asabys.com/gradient-denervation-technologies-enrolls-first-patient-in-early-feasibility-study-of-pulmonary-artery-denervation-system/) - Our recent activity Gradient Denervation Technologies Enrolls First Patient in Early Feasibility Study of Pulmonary Artery Denervation System FDA-Approved US study intended to evaluate pulmonary artery denervation in heart failure patients with WHO Group 2 Pulmonary Hypertension Gradient Denervation Technologies, a Paris-based medical device company developing a minimally-invasive, ultrasound-based device designed to treat pulmonary hypertension patients
- [Mahana Therapeutics Acquires Cara Care to Become a Global Leader in the Digital Treatment of Chronic Conditions](https://asabys.com/mahana-therapeutics-acquires-cara-care-to-become-a-global-leader-in-the-digital-treatment-of-chronic-conditions/) - Our recent activity Mahana Therapeutics Acquires Cara Care to Become a Global Leader in the Digital Treatment of Chronic Conditions READ THIS NEWS IN SPANISH Acquisition adds four digital treatment programs targeting significant populations to Mahana’s growing digestive health portfolio Combined company now has global reach with Cara Care’s IBS program currently being prescribed and
- [XRHealth Secures $6 Million in Funding Led By Asabys Partners and Welcomes NOVA Prime as a New Investor](https://asabys.com/xrhealth-secures-6-million-in-funding-led-by-asabys-partners-and-welcomes-nova-prime-as-a-new-investor/) - Our recent activity XRHealth Secures $6 Million in Funding Led By Asabys Partners and Welcomes NOVA Prime as a New Investor Funding will Support Development of AI Clinician, Using Spatial Computing XRHealth, the leading healthcare platform in Spatial computing, announced today that the company secured $6 million in funding led by Asabys Partners, with the participation of NOVA Prime Fund, a
- [ALLOX, a new Centre for Genomic Regulation spin-off, is launched with the support of Asabys](https://asabys.com/allox-a-new-centre-for-genomic-regulation-spin-off-is-launched-with-the-support-of-asabys/) - Our recent activity ALLOX, a new Centre for Genomic Regulation spin-off, is launched with the support of Asabys READ THIS NEWS IN SPANISH ALLOX is a spin-off from the Centre for Genomic Regulation in Barcelona, and is founded by the researchers Ben Lehner, Júlia Domingo, Pablo Baeza and Andre Faure. The company is developing a
- [El ICF invierte 10M€ en el fondo II de Asabys, que ya cuenta con 3 empresas participadas](https://asabys.com/el-icf-invierte-10me-en-el-fondo-ii-de-asabys-que-ya-cuenta-con-3-empresas-participadas/) - Our recent activity El ICF invierte 10M€ en el fondo II de Asabys, que ya cuenta con 3 empresas participadas READ THIS NEWS IN CATALAN READ THIS NEWS IN ENGLISH Sabadell Asabys II anunció el primer cierre del fondo de €100M a principios de año, y ya ha realizado 3 inversiones: DeepUll, OrikineBio y Gradient
- [Asabys launches a new €200m fund to invest in biotech & healthtech](https://asabys.com/asabys-launches-a-new-e200m-fund-to-invest-in-biotech-healthtech/) - Our recent activity Asabys launches a new €200m fund to invest in biotech & healthtech READ THIS NEWS IN SPANISH The fund’s first closing is expected by the end of this year, with commitments from institutional and private investors such as Banc Sabadell and the Alantra Investment Pool (Alantra & Mutua). SAHII 2 will invest
- [SABADELL-ASABYS HEALTH INNOVATION INVESTMENTS, SCR, SA GESTIONADO POR ASABYS PARTNERS ANUNCIA SU TERCER CIERRE CON LA PARTICIPACIÓN DEL ICO Y LA INCORPORACIÓN DE MAITE MALET](https://asabys.com/sabadell-asabys-health-innovation-investments-anuncia-su-tercer-cierre-con-la-participacion-del-ico-y-la-incorporacion-de-maite-malet/) - Our recent activity SABADELL-ASABYS HEALTH INNOVATION INVESTMENTS, SCR, SA GESTIONADO POR ASABYS PARTNERS ANUNCIA SU TERCER CIERRE CON LA PARTICIPACIÓN DEL ICO Y LA INCORPORACIÓN DE MAITE MALET Asabys Partners anunció hoy su tercer cierre materializado el pasado 24 de febrero de 2020, en el que se incorpora como inversor principal FondICO Global tras la
- [El fondo Sabadell Asabys Health Innovation Investments arranca de la mano de Asabys Partners con un capital comprometido de 30 millones de Euros](https://asabys.com/el-fondo-sabadell-asabys-health-innovation-investments-arranca-de-la-mano-de-asabys-partners-con-un-capital-comprometido-de-30-millones-de-euros/) - Our recent activity El fondo Sabadell Asabys Health Innovation Investments arranca de la mano de Asabys Partners con un capital comprometido de 30 millones de Euros El fondo de inversión en biomedicina Sabadell Asabys con un tamaño objetivo de 70 millones de Euros ha iniciado su andadura con compromisos de 30M€ por parte de sus
- [SpliceBio Enters Collaboration with Spark Therapeutics to Develop a Gene Therapy Targeting an Inherited Retinal Disease](https://asabys.com/splicebio-enters-collaboration-with-spark-therapeutics-to-develop-a-gene-therapy-targeting-an-inherited-retinal-disease/) - Our recent activity SpliceBio Enters Collaboration with Spark Therapeutics to Develop a Gene Therapy Targeting an Inherited Retinal Disease. READ THIS NEWS IN SPANISH SpliceBio is eligible to receive upfront, opt-in and milestone payments up to $216 million plus royalties Spark secures exclusive worldwide rights to SpliceBio’sproprietary Protein Splicing platform to develop, manufacture, and commercialize
- [Sidekick Health announces landmark acquisition, expanding its portfolio to offer regulated Prescription Digital Therapeutics](https://asabys.com/sidekick-health-announces-landmark-acquisition-expanding-its-portfolio-to-offer-regulated-prescription-digital-therapeutics/) - Our recent activity Sidekick Health announces landmark acquisition, expanding its portfolio to offer regulated Prescription Digital Therapeutics READ THIS NEWS IN SPANISH The acquisition of aidhere strengthens Sidekick Health’s digital health offering to patients and partners with the world’s leading PDT company. Sidekick Health, a global leader in digital health innovation, is poised to transform
- [Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline](https://asabys.com/agomab-raises-100-million-series-c-to-advance-fibrosis-focused-pipeline/) - Our recent activity Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline. READ THIS NEWS IN SPANISH Round led by Fidelity Management & Research Company with participation from new investors EQT Life Sciences, Canaan and Dawn Biopharma, a platform controlled by KKR, as well as existing investors Proceeds will support clinical Phase 2 stage
- [Agomab Receives FDA Fast Track Designation for AGMB-129 in Fibrostenosing Crohn’s Disease and Starts STENOVA Phase 2a Clinical Trial](https://asabys.com/agomab-receives-fda-fast-track-designation-for-agmb-129-in-fibrostenosing-crohns-disease-and-starts-stenova-phase-2a-clinical-trial/) - Our recent activity Agomab Receives FDA Fast Track Designation for AGMB-129 in Fibrostenosing Crohn’s Disease and Starts STENOVA Phase 2a Clinical Trial FDA Fast Track designation received for AGMB-129 in Fibrostenosing Crohn’s Disease. Global 12-week Phase 2a trial will evaluate Agomab’s oral GI-restricted small molecule ALK5 inhibitor in 36 patients with symptomatic Fibrostenosing Crohn’s Disease.
- [INBRAIN Neuroelectronics announces FDA Breakthrough Device designation for its graphene-based intelligent network modulation platform](https://asabys.com/inbrain-neuroelectronics-announces-fda-breakthrough-device-designation-for-its-graphene-based-intelligent-network-modulation-platform/) - Our recent activity INBRAIN Neuroelectronics announces FDA Breakthrough Device designation for its graphene-based intelligent network modulation platform A first-of-a-kind device, the INBRAIN Intelligent Network Modulation System is designed to offer a new treatment option for patients with Parkinson’s disease. It harnesses the properties of graphene and the power of machine learning software to provide highly
- [Gradient Denervation Technologies closes €14m Series A led by Sabadell Asabys](https://asabys.com/gradient-denervation-technologies-closes-e14m-series-a-led-by-sabadell-asabys/) - Our recent activity Gradient Denervation Technologies closes €14m Series A led by Sabadell Asabys READ THIS NEWS IN SPANISH Thuja Capital and founding investor Sofinnova Partners also joined the round The funds will enable the company to advance the clinical development of its unique, minimally invasive ultrasound-based catheter for the treatment of pulmonary hypertension, with
- [Sabadell Asabys invests in DeepUll extending its Series B to €17M](https://asabys.com/sabadell-asabys-invests-in-deepull-extending-its-series-b-to-e17m/) - Our recent activity Sabadell Asabys invests in DeepUll extending its Series B to €17M READ THIS NEWS IN SPANISH DeepUll is the first investment of Asabys’ second fund, announced last week. Asabys and Werfen co-lead the round, joining current shareholders Innvierte, Kurma Partners, Alta Life sciences, UI Investissement (advised by Mérieux Equity Partners) and Axis.
- [Orikine Bio closes €5.5m Series Seed Financing with Sabadell Asabys and AdBio](https://asabys.com/orikine-bio-closes-e5-5m-series-seed-financing-with-sabadell-asabys-and-adbio/) - Our recent activity Orikine Bio closes €5.5m Series Seed Financing with Sabadell Asabys and AdBio READ THIS NEWS IN SPANISH New synthetic biology spin-off from the Centre for Genomic Regulation (CRG) in Barcelona developing a novel proprietary platform for cytokine-based therapies targeting autoimmune and inflammatory diseases and founded by AdBio Partners in 2022 Sabadell Asabys
- [ONA Therapeutics Announces the Appointment of Dr Pamela Klein to its Board of Directors](https://asabys.com/ona-therapeutics-announces-the-appointment-of-dr-pamela-klein-to-its-board-of-directors/) - Our recent activity ONA Therapeutics Announces the Appointment of Dr Pamela Klein to its Board of Directors Leading medical oncologist and seasoned biotechnology executive with significant experience in drug development ONA Therapeutics (“ONA”), which is specialized in unravelling novel biology to design biopharmaceuticals attacking advanced cancer, is pleased to announce the appointment of Dr. Pamela
- [XRHealth and Amelia Virtual Care Announce Merger, Creating the Largest XR Therapeutics Platform in the World](https://asabys.com/xrhealth-and-amelia/) - Our recent activity XRHealth and Amelia Virtual Care Announce Merger, Creating the Largest XR Therapeutics Platform in the World READ THIS NEWS IN SPANISH Both Companies will Be merged Under the XRHealth Brand Name and By the End of the Year Are Forecasted to Have over 500K VR Treatments, Exceed 25K Patients Treated, and Be
- [Medasense selected as one of “Fierce 15 Medtech Companies of 2022”](https://asabys.com/medasense-selected-as-one-of-fierce-15-medtech-companies-of-2022/) - Our recent activity Medasense selected as one of “Fierce 15 Medtech Companies of 2022” As the opioid epidemic exacerbates the complex field of pain management, Israel’s Medasense Biometrics is on a mission to quantify and personalize patient suffering. At the heart of that quest is the company’s artificial-intelligence-powered patient monitor designed to track nociception, or
- [FDA authorizes marketing of Medasense's NOL® (nociception level index) technology through a De Novo grant](https://asabys.com/fda-authorizes-marketing-of-medasenses-nol-nociception-level-index-technology-through-a-de-novo-grant/) - Our recent activity FDA authorizes marketing of Medasense's NOL® (nociception level index) technology through a De Novo grant Medasense Biometrics Ltd. announced today that the U.S. Food and Drug Administration (FDA) has granted marketing authorization to the PMD-200 patient monitor with NOL® technology developed for monitoring nociception (the physiological response to pain) through the De Novo premarket review
- [Asabys announces the first close of its fund, with commitments of €100M, and appoints Sylvain Sachot and Guillem Masferrer as partners](https://asabys.com/asabys-announces-the-first-close-of-its-fund-with-commitments-of-e100m-and-appoints-sylvain-sachot-and-guillem-masferrer-as-partners/) - Our recent activity Asabys announces the first close of its fund, with commitments of €100M, and appoints Sylvain Sachot and Guillem Masferrer as partners READ THIS NEWS IN SPANISH Asabys has announced the 1st closing of its 2nd fund, with commitments of €100 million. The firm’s goal is to reach €200 million this year, to
- [Agomab Therapeutics Selected as One of Fierce Biotech's "Fierce 15" Companies of 2022](https://asabys.com/agomab-therapeutics-selected-as-one-of-fierce-biotechs-fierce-15-companies-of-2022/) - Our recent activity Agomab Therapeutics Selected as One of Fierce Biotech's "Fierce 15" Companies of 2022 Agomab Therapeutics NV (‘Agomab’) today announced that Fierce Biotech has named the company as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry. Agomab is a Belgian-headquartered
- [Agomab Raises Additional $40.5 Million Through Series B Extension Bringing Total Amount to $114M](https://asabys.com/agomab-raises-additional-40-5-million-through-series-b-extension-bringing-total-amount-to-114m/) - Our recent activity Agomab Raises Additional $40.5 Million Through Series B Extension Bringing Total Amount to $114M READ THIS NEWS IN SPANISH ● Extension led by Pfizer with participation from new investors Walleye Capital and Asabys Partners as well as existing investors ● Funding will support next stage of clinical and corporate development Agomab Therapeutics
- [Amelia Virtual Care welcomes new investors and strengthens its management team](https://asabys.com/amelia-virtual-care-welcomes-new-investors-and-strengthens-its-management-team/) - Our recent activity Amelia Virtual Care welcomes new investors and strengthens its management team● ENDRA and CDTI Innvierte lead the new investment bringing up to €7million the total funds raised by the company in the last year, together with current investors Sabadell Asabys, Caixa Capital Risc and CG Ventures ● Amelia Virtual Care, previously known
- [Digital digestive health therapeutic Cara Care lands $7M investment, appoints James “Jim” Mapes CEO](https://asabys.com/digital-digestive-health-therapeutic-cara-care-lands-7m-investment-appoints-james-jim-mapes-ceo-2/) - Our recent activity Digital digestive health therapeutic Cara Care lands $7M investment, appoints James “Jim” Mapes CEO● The rapidly expanding Berlin-based company attracted international food and nutrition manufacturer Dr. Schär AG as a new investor in an equity financing round, bringing its total raised to $16M. Current investors Sabadell Asabys and Johnson & Johnson Innovation
- [Nuage Therapeutics appoints biotech entrepreneur and executive Judit Anido as CEO](https://asabys.com/nuage-therapeutics-appoints-biotech-entrepreneur-and-executive-judit-anido-as-ceo/) - Our recent activity Nuage Therapeutics appoints biotech entrepreneur and executive Judit Anido as CEO READ THIS NEWS IN SPANISH Judit Anido joins Nuage Therapeutics as co-founder and CEO and becomes member of the Board of Directors. The company, pioneer in biomolecular condensation research, develops new drugs targeted to currently “undruggable” therapeutic targets Nuage Therapeutics, a
- [Digital Therapeutics Leader Sidekick Raises $55M Series B To Drive Further Growth](https://asabys.com/digital-therapeutics-leader-sidekick-raises-55m-series-b-to-drive-further-growth/) - Our recent activity Digital Therapeutics Leader Sidekick Raises $55M Series B To Drive Further Growth READ THIS NEWS IN SPANISH The closing of the company’s B Series follows an oversubscribed $20m A round in 2020. The funding allows Sidekick to accelerate the multi-chronic capabilities of its therapeutics platform. The company is accelerating its growing commercial
- [Asabys Partners da entrada al FEI y eleva su primer fondo a 117 millones](https://asabys.com/asabys-partners-da-entrada-al-fei-y-eleva-su-primer-fondo-a-117-millones/) - Our recent activity Asabys Partners da entrada al FEI y eleva su primer fondo a 117 millones https://www.expansion.com/catalunya/2022/02/18/620ea6ed468aeb34408b45d3.html Related news PortfolioOriva Therapeutics appoints Dr Agnès Arbat as CEO to advance clinical-stage women’s health pipeline June 11, 2026 Oriva Therapeutics appoints Dr Agnès Arbat as CEO to advance clinical-stage women’s health pipeline READ THIS NEWS IN
- [SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline](https://asabys.com/splicebio-raises-eur-50m-in-oversubscribed-series-a-financing-to-advance-protein-splicing-platform-and-expand-gene-therapy-pipeline/) - Our recent activity SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline READ THIS NEWS IN SPANISH Financing co-led by UCB Ventures and Ysios Capital with participation by New Enterprise Associates, Gilde Healthcare, Novartis Venture Fund and Asabys Partners Unique Protein Splicing platform enables efficient
- [“Cara Care for IBS” approved as a prescription digital therapeutic – German health insurances will reimburse the costs with a medical prescription for 90% of Germans](https://asabys.com/cara-care-for-ibs-approved-as-a-prescription-digital-therapeutic-german-health-insurances-will-reimburse-the-costs-with-a-medical-prescription-for-90-of-germans/) - Our recent activity “Cara Care for IBS” approved as a prescription digital therapeutic – German health insurances will reimburse the costs with a medical prescription for 90% of GermansPatients with irritable bowel syndrome (IBS) gain access to a prescription digital therapeutic. The multimodal treatment is based on nutrition therapy, elements of cognitive-behavioral therapy, and gut-directed
- [Agomab Therapeutics Completes Acquisition of Origo Biopharma](https://asabys.com/agomab-therapeutics-completes-acquisition-of-origo-biopharma/) - Our recent activity Agomab Therapeutics Completes Acquisition of Origo Biopharma Agomab Therapeutics NV (‘Agomab’) announced today the closing of the Origo Biopharma acquisition. The transaction, first announced on October 28th, 2021, combines Spanish biotech Origo Biopharma and its pipeline of organ-restricted small molecule drug candidates targeting the transforming growth factor beta (TGF-β) pathway with Agomab’s
- [ONA Therapeutics Appoints Dr Michel Detheux as Independent Chair to Board of Directors](https://asabys.com/ona-therapeutics-appoints-dr-michel-detheux-as-independent-chair-to-board-of-directors/) - Our recent activity ONA Therapeutics Appoints Dr Michel Detheux as Independent Chair to Board of Directors Seasoned biotech executive with a wealth of experience and a track-record of strategic alliances in the immuno-oncology space ONA Therapeutics (“ONA”), which is focused on the discovery and development of therapeutic biologics targeting lipid metabolism to treat advanced cancer,
- [Agomab Therapeutics to Acquire Origo Biopharma](https://asabys.com/agomab-therapeutics-to-acquire-origo-biopharma/) - Our recent activity Agomab Therapeutics to Acquire Origo Biopharma READ THIS NEWS IN SPANISH Acquisition strengthens Agomab as a leader in targeting growth factor pathways Origo brings TGF-β-targeted approach with clinical-stage program in Crohn’s disease and preclinical candidate for idiopathic pulmonary fibrosis Agomab will integrate Origo’s small molecule development platform, team and R&D facilities Agomab
- [Anaconda Biomed to close a venture debt of up to 10M€ by the EIB to treat acute ischemic stroke (AIS)](https://asabys.com/anaconda-biomed-to-close-a-venture-debt-of-up-to-10me-by-the-eib-to-treat-acute-ischemic-stroke-ais/) - Our recent activity Anaconda Biomed to close a venture debt of up to 10M€ by the EIB to treat acute ischemic stroke (AIS) EIB to provide venture debt funding of up to €10 million to support the development of Anaconda’s next generation of catheters to treat acute ischemic strokes This venture debt operation is supported
- [ONA Therapeutics Strengthens Scientific Leadership Team](https://asabys.com/ona-therapeutics-strengthens-scientific-leadership-team/) - Our recent activity ONA Therapeutics Strengthens Scientific Leadership Team Industry veteran in oncology antibody discovery & development Dr Haijun Sun appointed Chief Scientific Officer Expansion of the Scientific Advisory Board with appointments of leading experts inpreclinical, translational and clinical drug development Barcelona, Spain, 21 October 2021: ONA Therapeutics (“ONA”), which is focused on the discovery
- [Nuage Therapeutics, the spin-off from IRB Barcelona and ICREA, is launched with the support of Asabys](https://asabys.com/nuage-therapeutics-the-spin-off-from-irb-barcelona-and-icrea-is-launched-with-the-support-of-asabys/) - Our recent activity Nuage Therapeutics, the spin-off from IRB Barcelona and ICREA, is launched with the support of Asabys READ THIS NEWS IN SPANISH Nuage Therapeutics is a spin-off of IRB Barcelona and ICREA and was founded by the researchers Xavier Salvatella, Mateusz Biesaga and Denes Hnisz. The company is based at the Barcelona Science
- [La spin-off del IRB Ona Therapeutics arranca de la mano de Sabadell Asabys](https://asabys.com/la-spin-off-del-irb-ona-therapeutics-arranca-de-la-mano-de-sabadell-asabys-2/) - Our recent activity La spin-off del IRB Ona Therapeutics arranca de la mano de Sabadell Asabys Ona Therapeutics ha anunciado hoy el cierre de una ronda de financiación semilla de 1,5 millones de euros aportados en su totalidad por Sabadell Asabys, vehículo gestionado por Asabys Partners dedicado a la inversión en innovación en salud. Con
- [Alantra enters venture capital via strategic partnership with Asabys Partners](https://asabys.com/alantra-enters-venture-capital-via-strategic-partnership-with-asabys-partners/) - Our recent activity Alantra enters venture capital via strategic partnership with Asabys Partners, a healthcare and life sciences innovation VC firm backed by Banc Sabadell as anchor investor Barcelona / Madrid, 17 July 2019 – Asabys Partners (“Asabys”), a Pan-European Venture Capital firm specialized in investments in the life sciences and health sectors, and Alantra, an
- [ANACONDA BIOMED S.L. secures €20 Million round of funding](https://asabys.com/anaconda-biomed-s-l-secures-e20-million-round-of-funding/) - Our recent activity ANACONDA BIOMED S.L. secures €20 Million round of funding READ THIS NEWS IN SPANISH Anaconda Biomed S.L., a medical technology company developing next-generation thrombectomy systems for the treatment of ischemic stroke, has closed €20 million in new funding. The funding will be used for clinical studies of the company’s groundbreaking technology, regulatory submissions in international
- [Sabadell ASABYS y Alta Life Sciences colideran la inversión en INBRAIN NEUROELECTRONICS](https://asabys.com/sabadell-asabys-y-alta-life-sciences-colideran-la-inversion-en-inbrain-neuroelectronics/) - Our recent activity Sabadell ASABYS y Alta Life Sciences colideran la inversión en INBRAIN NEUROELECTRONICS INBRAIN, spin-off del Instituto Catalán de Nanociencia y Nanotecnología (ICN2) e ICREA fundada en 2019 en Barcelona, se dedica al desarrollo de terapias de neuromodulación utilizando una interfaz neuronal revolucionaria basada en grafeno para registrar y modular señales neuronales ligadas a trastornos neurológicos, con
- [Sylvain Sachot se incorpora como director de inversiones en Asabys Partners](https://asabys.com/sylvain-sachot-se-incorpora-como-director-de-inversiones-en-asabys-partners/) - Our recent activity El fondo Sabadell Asabys Health Innovation Investments incorpora a Sylvain Sachot como Director de Inversiones de Asabys Partners. Asabys Partners, una firma de capital riesgo centrada en la innovación de la salud con sede en Barcelona, España, anunció hoy que había nombrado a Sylvain Sachot como Director de Inversiones. Sylvain será responsable de supervisar
- [Guillem Masferrer se incorpora como asociado en Asabys partners](https://asabys.com/guillem-masferrer-se-incorpora-como-asociado-en-asabys-partners/) - Our recent activity El fondo Sabadell Asabys Health Innovation Investments incorpora a Guillem Masferrer como Asociado de Asabys Partners. Asabys Partners, una firma de capital riesgo centrada en la innovación de la salud con sede en Barcelona, España, anunció hoy que había nombrado a Guillem Masferrer como Asociado de inversiones. Guillem se centrará, por un
- [El fondo Sabadell Asabys Health Innovation Investments incorpora a Andrea Sáez como Asociada de Asabys Partners](https://asabys.com/andrea-saez-se-incorpora-como-asociada-en-asabys-partners/) - Our recent activity El fondo Sabadell Asabys Health Innovation Investments incorpora a Andrea Sáez como Asociada de Asabys Partners Asabys Partners, una firma de capital riesgo centrada en la innovación de la salud con sede en Barcelona, España, anunció hoy que había nombrado a Andrea Sáez como Asociada de inversiones. Andrea se especializará en las
- [Psious cierra una ronda de financiación de 8 millones de euros liderada por Asabys Partners](https://asabys.com/psious-cierra-una-ronda-de-financiacion-de-8-millones-de-euros-liderada-por-asabys-partners/) - Our recent activity Psious cierra una ronda de financiación de 8 millones de euros con la participación de Sabadell Asabys, Caixa Capital Risc y Sabadell Venture Capital Barcelona, 03 de mayo de 2019.- Psious ha anunciado el cierre de una ronda de financiación de 8 millones de Euros. La ronda ha sido co-liderada por Sabadell Asabys
- [Cara Care Raises $7M Series](https://asabys.com/cara-care-raises-7m-series/) - Our recent activity Cara Care Raises $7M Series A Led by Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and Asabys Partners READ THIS NEWS IN SPANISH Digital health company HiDoc Technologies GmbH, dba Cara Care, today announced that it has raised $7 million in Series A funding. The round was led by JJDC and Barcelona-based
- [Ona Therapeutics raises €30M in Series A financing](https://asabys.com/ona-therapeutics-raises-e30m-in-series-a-financing/) - Our recent activity Ona Therapeutics raises €30M in Series A financing READ THIS NEWS IN SPANISH Ona Therapeutics, which is focused on the discovery and development of therapeutic biologics to treat metastatic cancer, announces today the closing of a €30 million Series A financing, with the participation from existing investor Asabys Partners and new investors
- [Origo Biopharma raises 2,3M€ in Series Seed financing](https://asabys.com/origo-biopharma-raises-2-3m-in-series-seed-financing/) - Our recent activity Origo Biopharma raises 2,3M€ in Series Seed financing READ THIS NEWS IN SPANISH Origo Biopharma announced today the closing of a €2,3 million Series Seed financing, with the participation from Sabadell Asabys, XesGalicia and the founding shareholders. The financing, led by Sabadell Asabys, will allow the biotech to complete the pre-clinical development and move its
- [ASABYS PARTNERS anuncia la incorporación de Anna Bellmunt](https://asabys.com/asabys-partners-anuncia-la-incorporacion-de-anna-bellmunt/) - Our recent activity ASABYS PARTNERS anuncia la incorporación de Anna Bellmunt Asabys Partners anunció hoy la incorporación de Anna Bellmunt al equipo de inversiones de la compañía. Anna proviene de la firma internacional LSP (Life Science Partners). LSP es una de las principales firmas de capital riesgo europeas en el ámbito de las ciencias de la vida, con
- [ProteoDesign announces new Investment led by Ysios Capital and rebrands as Splice Bio](https://asabys.com/proteodesign-announces-new-investment-led-by-ysios-capital-and-rebrands-as-splice-bio/) - Our recent activity ProteoDesign announces new Investment led by Ysios Capital and rebrands as Splice Bio READ THIS NEWS IN SPANISH Splice Bio, a biotech company based on technology developed in the Muir Lab at Princeton University, announced today a new investment into the Company led by Ysios Capital and joined by Asabys Partners from its fund Sabadell Asabys.
- [Israeli Pain Monitoring Startup Medasense Raises $18M in Series C Round](https://asabys.com/israeli-pain-monitoring-startup-medasense-raises-18m-in-series-c-round/) - Our recent activity Israeli Pain Monitoring Startup Medasense Raises $18M in Series C Round READ THIS NEWS IN SPANISH Considering the complex nature of pain, Medasense technology uses a unique multi- parametric sensor platform and advanced AI algorithms to convert complicated data into a patient’s “Signature of Pain”. The technology, which is currently utilized in operating rooms
- [Ona Therapeutics is named as one of Fierce Biotech’s “Fierce 15” Biotech Companies of 2020](https://asabys.com/ona-therapeutics-is-named-as-one-of-fierce-biotechs-fierce-15-biotech-companies-of-2020/) - Our recent activity Ona Therapeutics is named as one of Fierce Biotech’s “Fierce 15” Biotech Companies of 2020 Ona Therapeutics, which is focused on the discovery and development of therapeutic biologics to treat metastatic cancer, today announced that it has been named by Fierce Biotech as one of 2020’s Fierce 15 biotechnology companies, designating it
- [Medlumics raises €14M in a Series e financing co-led by Asabys Partners](https://asabys.com/medlumics-raises-e14m-in-a-series-e-financing-co-led-by-asabys-partners/) - Our recent activity Medlumics raises €14M in a Series e financing co-led by Asabys Partners, VI partners and CDTI Innvierte, together with existing investors Andera Partners, Caixa Capital Risc and Innogest READ THIS NEWS IN SPANISH Medlumics, which develops Ablaview®, a unique RF irrigated ablation catheter system that merges photonics and miniaturized optics to guide
- [Digital therapeutics leader Sidekick raises $20M in Series A funding round led by Wellington and Asabys](https://asabys.com/digital-therapeutics-leader-sidekick-raises-20m-in-series-a-funding-round-led-by-wellington-and-asabys-2/) - Our recent activity Digital therapeutics leader Sidekick raises $20M in Series A funding round led by Wellington and Asabys READ THIS NEWS IN SPANISH Nordic digital therapeutics company Sidekick Health has completed a $20 million oversubscribed Series A financing round led by Wellington Partners and Asabys Partners, through its fund SAHII, with participation by existing investors Novator and Frumtak Ventures.
- [Splice Bio appoints Jean-Philippe Combal as Chairman of the Board of Directors](https://asabys.com/splice-bio-appoints-jean-philippe-combal-as-chairman-of-the-board-of-directors/) - Our recent activity Splice Bio appoints Jean-Philippe Combal as Chairman of the Board of Directors READ THIS NEWS IN SPANISH Splice Bio, a gene therapy company based on technology developed in the Muir Lab at Princeton University, announced today that it has appointed Jean- Philippe Combal as Chairman of its Board of Directors. Dr. Combal
- [Koa Health Closes Oversubscribed €30M Series A to Accelerate Growth Following Spinout From Telefónica](https://asabys.com/koa-health-closes-oversubscribed-e30m-series-a-to-accelerate-growth-following-spinout-from-telefonica/) - Our recent activity Koa Health Closes Oversubscribed €30M Series A to Accelerate Growth Following Spinout From Telefónica 2020, led by Wellington Partners Life Sciences and Ancora Finance Group, and has now been fully closed with key participations from MTIP and Akilia Partners, and further contributions from Creas Impacto, Sabadell Asabys, and Mundi Ventures. As the
- [INBRAIN Neuroelectronics raises over €14M Series A led by Asabys Partners, Alta Life Sciences and CDTI to develop intelligent graphene-based neuroelectronic therapies for brain related disorders](https://asabys.com/inbrain-neuroelectronis-raises-over-14m-series-a/) - Our recent activity INBRAIN Neuroelectronics raises over €14M Series A led by Asabys Partners, Alta Life Sciences and CDTI to develop intelligent graphene-based neuroelectronic therapies for brain related disorders READ THIS NEWS IN SPANISH Barcelona, March 26th, 2021 INBRAIN Neuroelectronics is a spin-off company from Graphene Flaship partners’ the Catalan Institute of Nanoscience and Nanotechnology
- [Asabys Partners certifies with Bureau Veritas its Social Responsibility Management System aligned with the Sustainable Development Goals (SDGs) from United Nations](https://asabys.com/asabys-partners-certifies-with-bureau-veritas-its-social-responsibility-management-system-aligned-with-the-sustainable-development-goals-sdgs-from-united-nations/) - Our recent activity Asabys Partners certifies with Bureau Veritas its Social Responsibility Management System aligned with the Sustainable Development Goals (SDGs) from United Nations Asabys Partners, venture capital firm investing in innovative companies within the healthcare space, announces today the certification of its management system of CSR aligned with the Sustainable Development Goals from United
- [Merck and INBRAIN Neuroelectronics Collaborate to Develop the Next Generation of Bioelectronic Therapies](https://asabys.com/merck-and-inbrain-neuroelectronics-collaborate-to-develop-the-next-generation-of-bioelectronic-therapies/) - Our recent activity Merck and INBRAIN Neuroelectronics Collaborate to Develop the Next Generation of Bioelectronic Therapies READ THIS NEWS IN SPANISH Innovation Center project of Merck collaborates to develop smart neuro-modulation for targeted treatment of chronic diseases Joint development agreement represents a promising step towards a highly selective and efficient next generation of bioelectronic therapies
- [#EntrevistaBiospain2021 | Asabys, el primer inversor de salud español acreditado por su compromiso con los Objetivos de Desarrollo Sostenible](https://asabys.com/asabys-el-primer-inversor-de-salud-espanol-acreditado-por-su-compromiso-con-los-objetivos-de-desarrollo-sostenible/) - Our recent activity #EntrevistaBiospain2021 | Asabys, el primer inversor de salud español acreditado por su compromiso con los Objetivos de Desarrollo Sostenible Hablamos con Clara Campàs y Josep Lluís Sanfeliu, fundadores del fondo de capital riesgo Asabys Partners, Silver Sponsor de Biospain 2021, sobre su compromiso con la sostenibilidad y el futuro de la biotecnología

## Pages

- [Home](https://asabys.com/) - Fostering breakthrough innovation in healthcareAsabys is an investment firm based in Barcelona, investing in healthcare and life-sciences innovation. PORTFOLIO TEAM Impact We want to push the boundaries of science and medicine improving patient’s life Disruptive We look for highly innovative and transformative technologies Hands-on We consider ourselves partners and collaborators to our portfolio
- [Montse Vendrell](https://asabys.com/team/montse-vendrell/) - Montse VendrellPartner Partner at Asabys. Montse currently serves on the board of directors of Ona Therapeutics, InBrain Neuroelectronics, Peptomyc and Accure. She is also independent director at the board of Oryzon genomics. Formerly, Montse was partner at Aliath Bioventures and Alta Life Sciences. Prior to that, she was CEO of Biocat, BIST (Barcelona Institute of
- [Canal de Denuncias](https://asabys.com/canaldenuncias/) - CANAL INTERNO DE INFORMACIÓN (CANAL DE DENUNCIAS) ASABYS PARTNERS, S.G.E.I.C., S.A. dispone de un Sistema Interno de Información conforme a la Ley 2/2023, de 20 de febrero, reguladora de la protección de las personas que informen sobre infracciones normativas y de lucha contra la corrupción. Este canal permite comunicar, de forma confidencial y, si
- [Pilar Almajano](https://asabys.com/team/pilar-almajano/) - Pilar AlmajanoFinancial Controller Pilar joined Asabys in 2025 as Financial Controller, where she is responsible for financial operations, accounting and investor reporting. Prior to joining Asabys, she was a Manager at EY Audit Services in Barcelona, working with clients across a wide range of sectors, including pharmaceuticals, retail and pool & wellness. Pilar holds a
- [Joana Correia](https://asabys.com/team/joana-correia/) - Joana CorreiaSenior Analyst Senior Investment Analyst. Joana joined Asabys in 2025 has part of the Aliath-Asabys integration. At Aliath Bioventures, Joana was involved in sourcing and assessing biotech investment opportunities. Prior to Aliath, Joana was an Investment Fellow at Ysios Capital and before her venture capital career, Joana contributed to a clinical research study in
- [Anna Bellmunt, PhD](https://asabys.com/team/anna-bellmunt-phd/) - Anna Bellmunt, PhDSenior Associate Senior Associate at Asabys, where she joined in 2021, Anna is responsible for sourcing and assessing opportunities from the scientific, development and business perspectives. Anna currently serves as a board observer at Ona Therapeutics and Nuage Therapeutics. Previously, Anna was Investment Analyst at LSP where she was responsible for the initial deal
- [Antonio Limatola](https://asabys.com/team/antonio-limatola/) - Antonio LimatolaSenior Associate Senior Associate at Asabys, where he joined in 2022. He is responsible for evaluating novel opportunities across multiple therapeutic areas in Biotech and HealthTech. Antonio currently serves as a board observer at Inbrain Neuroelectronics, SafeHeal and ALLOX. Antonio joined Asabys after working as Investment Analyst at Inkef Capital where he supported the Healthcare team
- [Isabel Jiménez](https://asabys.com/team/isabeljimenez/) - Isabel JiménezSenior Associate Principal at Asabys, where she joined in 2022 as an Associate, focusing on the assessment of novel opportunities from a scientific and strategic perspective in biotech and medtech. Isabel currently serves as a board observer at Orikine Bio and Augustine Therapeutics. Isabel has 10 years of experience in translational research and investments in
- [Clara Campàs, PhD](https://asabys.com/team/clara-campas-phd/) - Clara Campàs, PhDCo-founder and managing partner Managing partner and co-founder of Asabys. Clara currently serves on the board of directors of Ona Therapeutics, Nuage Therapeutics, ALLOX and Augustine Therapeutics. Formerly, Clara served as Strategy & Development Director at Kern Pharma and held several positions at Advancell, including being the managing director. Clara has served as
- [Sylvain Sachot, PhD](https://asabys.com/team/sylvain-sachot-phd/) - Sylvain Sachot, PhDPartner Partner at Asabys, Sylvain joined the firm at its inception in 2018. At Asabys, Sylvain is involved in the sourcing, execution, and management of our investments in the biopharma and medtech segments. He currently serves on the board of directors of Anaconda Biomed, Orikine Bio and Gradient Denervation Technologies. Previously, Sylvain spent
- [Josep Ll. Sanfeliu](https://asabys.com/team/josep-ll-sanfeliu/) - Josep Ll. SanfeliuCo-founder and managing partner Managing partner, president and co-founder at Asabys. Josep currently serves on the board of directors of SafeHeal, Inbrain Neuroelectronics, XRHealth and Medasense. Formerly, Josep co-founded Ysios Capital (2008-2018) where he was the partner in charge of Health Technology investments, investing in a total of 9 companies in the areas
- [Maite Malet](https://asabys.com/team/maite-malet/) - Maite MaletPrincipal Principal at Asabys, where she joined in 2019. Maite focuses on sourcing, executing, and managing investments across the firm’s healthtech portfolio and plays an active role in Asabys’ fundraising and corporate development initiatives. Maite currently serves as a board observer for Qida, XRHealth, Medasense, and Deepull. Before joining Asabys, Maite led Business Development at
- [Guillem Masferrer](https://asabys.com/team/guillem-masferrer/) - Guillem MasferrerPartner Partner at Asabys, where he joined in 2018. Guillem is primarily responsible for sourcing, executing, and managing investments, with a major focus in the firm’s health-tech portfolio. He is also leading Asabys’ deal structuring, transactions and negotiations. Guillem currently serves on the board of directors of Qida, Quibim, Sidekick and is an observer
- [Beatriz Gandarias](https://asabys.com/team/beatriz-gandarias/) - Beatriz GandariasSenior Associate Associate at Asabys. Prior to joining Asabys, Beatriz was an Associate at Aliath Bioventures (2021–2025), where she focused on venture capital investments in the life sciences sector. Previously, she worked in healthcare management and strategy consulting at Accenture, leading digital transformation projects such as the implementation of an AI- and Big Data–driven
- [Mònica Sabé](https://asabys.com/team/monica-sabe/) - Mònica SabéExecutive Assistant- Office Manager Executive Assistant- Office Manager Mònica has extensive experience as an Executive Assistant in corporate and multinational environments, providing strategic support to senior management teams. Before joining Asabys, she worked at Catalonia Hotels & Resorts as Executive Assistant to the CEO, and for over twenty years at McDonald’s Spain, where she
- [Laia Romero](https://asabys.com/team/laia-romero/) - Laia RomeroExecutive Assistant Executive Assistant Laia brings over 15 years of support experience across healthcare, science, and investment sectors. Before joining Asabys, she worked as Executive Assistant at Alta Life Sciences and Aliath Bioventures, gaining expertise in venture capital, and previously held roles at Biocat and the Barcelona Institute of Science and Technology. She combines
- [Jose María Fernández](https://asabys.com/team/jose-maria-fernandez/) - Jose María FernándezPartner Partner at Asabys. Jose Maria “Chema” Fernandez joined Asabys in October of 2025. Chema is involved in the sourcing, execution, and management of our investments. He currently serves on the board of directors of Deepull and Inbiomotion. Since 2017 he has been member of the Investment Committee of the fund Alta Life
- [Emilio Erazo-Fischer](https://asabys.com/team/emilio-erazo-fischer/) - Emilio Erazo-FischerOperating Partner Operating partner at Asabys, Emilio joined the team in December 2024. Emilio supports our biopharma portfolio investments in strategy and business development and currently holds the CBO role at ALLOX. Previously, Emilio led external innovation deals at Boehringer Ingelheim, as Director of Global BD&L Oncology, contributing novel pipeline assets and technology platforms.
- [Ioia Vallcorba](https://asabys.com/team/ioia-vallcorba/) - Ioia VallcorbaExecutive Assistant Executive Assistant at Asabys, in charge of investor and media relations and office operations. Previously, Ioia was Executive Assistant to the CEO at Corporación Genbad (Landon) and at Catalana d’Iniciatives, where she was in charge of office management (travel coordination, executives agendas, etc.), actively involved in communications and press release activities (mailing,
- [Núria Aloy](https://asabys.com/team/nuria-aloy/) - Núria AloyCFO CFO at Asabys, in charge of the administrative management, financial control, reporting to investors and risk management. Previously, Núria was the Administration manager at Ysios Capital, responsible for all administrative matters related to the management company and the funds. Also, Núria served as CFO and Portfolio Manager at Catalana d’Iniciatives where she was
- [CONTACT](https://asabys.com/contact/) - Tell us about your project CONTACT INFO Via Laietana, 26, 5th. floor 08003 Barcelona, Spain info@asabys.com
- [test](https://asabys.com/__trashed/) - Josep Ll. Sanfeliu Co-founder and managing partner Clara Campàs Co-founder and managing partner Sylvain Sachot Principal Guillem Masferrer Director Anna Bellmunt Associate Maite Malet Associate Núria Aloy CFO & Admin
- [new test](https://asabys.com/new-test/) - All Members Josep Ll. Sanfeliu Co-founder and managing partner Clara Campàs Co-founder and managing partner
- [DISCLAIMERS](https://asabys.com/legal-disclaimers/) - ASABYS PARTNERS Privacy policy www.asabys.com is an Internet domain owned by Sabadell Asabys Health Innovation Investments, S.A. (“ASABYS”), with present legal address at Passeig de Gràcia 53, àtic – 08007 Barcelona (Spain), and the Tax ID Number of which is A-67293829. It is registered at the Company Register of Barcelona, Book 46.606, Page 525.265, Folio1.
- [NEWS](https://asabys.com/news/) - AllPortfolioInternal
- [TEAM](https://asabys.com/team/) - All Members Josep Ll. Sanfeliu Co-founder and managing partner Clara Campàs Co-founder and managing partner Sylvain Sachot Partner Guillem Masferrer Partner Montse Vendrell Partner Jose María Fernández Partner Emilio Erazo-Fischer Operating Partner Núria Aloy CFO Maite Malet Principal Isabel Jimenez Principal Antonio Limatola Senior Associate Anna Bellmunt Senior Associate Beatriz Gandarias Senior Associate Pilar Almajano
- [PORTFOLIO](https://asabys.com/portfolio/) - Accure Therapeutics Accure Therapeutics Agomab Agomab ALLOX ALLOX Amelia Amelia Anaconda Anaconda Augustine Therapeutics Augustine Therapeutics Binx Health Binx Health Deepull Deepull Gradient Denervation Technologies Gradient Denervation Technologies Inbiomotion Inbiomotion Inbrain Neuroelectronics Inbrain Neuroelectronics Medasense Medasense Mediktor Mediktor Nuage Nuage Ona Therapeutics Ona Therapeutics Origo Biopharma Origo Biopharma Oriva Oriva Orikine Bio Orikine Bio Peptomyc

## Slides

- [Auto Draft](https://asabys.com/home_slider/auto-draft/)

## Portfolio

- [Oriva](https://asabys.com/portfolio/oriva/)
- [Ona Therapeutics](https://asabys.com/portfolio/ona-therapeutics/)
- [Qida](https://asabys.com/portfolio/qida/)
- [Binx Health](https://asabys.com/portfolio/binx/)
- [Orikine Bio](https://asabys.com/portfolio/orikine/)
- [Peptomyc](https://asabys.com/portfolio/peptomyc/)
- [Mediktor](https://asabys.com/portfolio/mediktor/)
- [Inbiomotion](https://asabys.com/portfolio/inbiomotion/)
- [Inbrain Neuroelectronics](https://asabys.com/portfolio/inbrain-neuroelectronics/)
- [Accure Therapeutics](https://asabys.com/portfolio/accure/)
- [XR Health](https://asabys.com/portfolio/amelia/)
- [Deepull](https://asabys.com/portfolio/deepull-2/)
- [SafeHeal](https://asabys.com/portfolio/safeheal/)
- [Origo Biopharma](https://asabys.com/portfolio/origo-biopharma/)
- [Amelia](https://asabys.com/portfolio/amelia-2/)
- [Quibim](https://asabys.com/portfolio/quibim/)
- [Augustine Therapeutics](https://asabys.com/portfolio/augustine-therapeutics/)
- [Anaconda](https://asabys.com/portfolio/anaconda/)
- [Agomab](https://asabys.com/portfolio/agomab/)
- [Gradient Denervation Technologies](https://asabys.com/portfolio/gradient-2/)
- [ALLOX](https://asabys.com/portfolio/allox-2/)
- [Nuage](https://asabys.com/portfolio/nuage/)
- [Sidekick](https://asabys.com/portfolio/sidekick/)
- [Medasense](https://asabys.com/portfolio/medasense/)
- [Splice Bio](https://asabys.com/portfolio/splice-bio/)

## WPM Team

- [Laia Romero](https://asabys.com/wpm-team/laia-romero/) - Your post content goes here.
- [Mònica Sabé](https://asabys.com/wpm-team/monica-sabe/) - Your post content goes here.
- [Joana Correia](https://asabys.com/wpm-team/joana-correia/) - Your post content goes here.
- [Beatriz Gandarias](https://asabys.com/wpm-team/beatriz-gandarias/) - Your post content goes here.
- [Jose María Fernández](https://asabys.com/wpm-team/jose-maria-fernandez/) - Your post content goes here.
- [Montse Vendrell](https://asabys.com/wpm-team/montse-vendrell/) - Your post content goes here.
- [Emilio Erazo-Fischer](https://asabys.com/wpm-team/emilio-erazo-fischer/) - Your post content goes here.
- [Maite Malet](https://asabys.com/wpm-team/maite-malet/) - Your post content goes here.
- [Clara Campàs](https://asabys.com/wpm-team/clara-campas/) - Your post content goes here.
- [Núria Aloy](https://asabys.com/wpm-team/nuria-aloy/) - Your post content goes here.
- [Isabel Jimenez](https://asabys.com/wpm-team/isabel-jimenez/) - Your post content goes here.
- [Anna Bellmunt](https://asabys.com/wpm-team/anna-bellmunt/) - Your post content goes here.

## Categories

- [Portfolio](https://asabys.com/category/portfolio/)
- [Internal](https://asabys.com/category/internal/)

## Project Categories

- [new portfolio](https://asabys.com/project-type/new-portfolio/)